Targeting HDAC Complexes in Asthma and COPD
Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate postt...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-09-01
|
| Series: | Epigenomes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4655/3/3/19 |
| _version_ | 1797758692232265728 |
|---|---|
| author | Martijn R. H. Zwinderman Sander de Weerd Frank J. Dekker |
| author_facet | Martijn R. H. Zwinderman Sander de Weerd Frank J. Dekker |
| author_sort | Martijn R. H. Zwinderman |
| collection | DOAJ |
| description | Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments. |
| first_indexed | 2024-03-12T18:33:45Z |
| format | Article |
| id | doaj.art-36725653806c4d0e954d62677059c81f |
| institution | Directory Open Access Journal |
| issn | 2075-4655 |
| language | English |
| last_indexed | 2024-03-12T18:33:45Z |
| publishDate | 2019-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Epigenomes |
| spelling | doaj.art-36725653806c4d0e954d62677059c81f2023-08-02T08:09:08ZengMDPI AGEpigenomes2075-46552019-09-01331910.3390/epigenomes3030019epigenomes3030019Targeting HDAC Complexes in Asthma and COPDMartijn R. H. Zwinderman0Sander de Weerd1Frank J. Dekker2Department of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The NetherlandsDepartment of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The NetherlandsDepartment of Chemical and Pharmaceutical Biology, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, 9713 AV Groningen, The NetherlandsAround three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments.https://www.mdpi.com/2075-4655/3/3/19asthmaCOPDinflammationNF-κBHDACacetylationpost translational modification (PTM)inhibitordrug designco-repressor complexreview |
| spellingShingle | Martijn R. H. Zwinderman Sander de Weerd Frank J. Dekker Targeting HDAC Complexes in Asthma and COPD Epigenomes asthma COPD inflammation NF-κB HDAC acetylation post translational modification (PTM) inhibitor drug design co-repressor complex review |
| title | Targeting HDAC Complexes in Asthma and COPD |
| title_full | Targeting HDAC Complexes in Asthma and COPD |
| title_fullStr | Targeting HDAC Complexes in Asthma and COPD |
| title_full_unstemmed | Targeting HDAC Complexes in Asthma and COPD |
| title_short | Targeting HDAC Complexes in Asthma and COPD |
| title_sort | targeting hdac complexes in asthma and copd |
| topic | asthma COPD inflammation NF-κB HDAC acetylation post translational modification (PTM) inhibitor drug design co-repressor complex review |
| url | https://www.mdpi.com/2075-4655/3/3/19 |
| work_keys_str_mv | AT martijnrhzwinderman targetinghdaccomplexesinasthmaandcopd AT sanderdeweerd targetinghdaccomplexesinasthmaandcopd AT frankjdekker targetinghdaccomplexesinasthmaandcopd |